BCTX

BriaCell Therapeutics Corp · NASDAQ

Sector Health Technology
Industry Biotechnology
Website briacell.com
Employees(FY) 16
ISIN CA1079302081

Performance

-17.92%

-41.63%

-56.7%

-54.65%

-41.0%

YTD

-91.91%

Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

Advanced Technical Analysis

Technical Analysis of BCTX 2025-02-03

The stock indicators suggest a mixed sentiment, with the Moving Average Score indicating a bearish outlook at 3, while the Oscillators Score reflects a neutral stance at 53, and the overall Technical Score at 6 also points to bearish conditions. This combination implies a cautious market environment, with potential for volatility as the indicato...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of BCTX

Stock Rank

Recent News & Updates

2024-06-14 09:52
BCTX Stock Earnings: BriaCell Therapeutics Beats EPS for Q3 2024(Investorplace)
2024-06-02 20:00
BriaCell Presents Clinical Efficacy Data at ASCO 2024(Globenewswire)
2024-05-29 20:00
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer(Globenewswire)
2024-05-27 20:00
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study(Globenewswire)
2024-05-27 19:27
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-05-23 20:00
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024(Globenewswire)
2024-05-20 19:39
Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday(Investorplace)
2024-05-17 04:33
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering(Globenewswire)
2024-05-14 20:00
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering(Globenewswire)
2024-04-23 20:00
BriaCell Announces Oral and Poster Presentations at ASCO 2024(Globenewswire)
2024-04-09 20:00
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer(Globenewswire)
2024-04-08 20:00
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR(Globenewswire)
2024-03-18 18:52
BCTX Stock Earnings: BriaCell Therapeutics Reported Results for Q2 2024(Investorplace)
2024-03-06 19:00
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies(Globenewswire)
2024-03-05 19:00
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference(Globenewswire)
2024-02-26 19:00
BriaCell Provides Update on Alleged Illegal Trading of Public Securities(Globenewswire)
2024-02-06 19:00
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case(Globenewswire)
2024-02-05 19:30
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing(Globenewswire)
2024-01-30 09:48
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting(Globenewswire)
2024-01-03 19:45
BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with Eye-Bulging Metastatic Breast Cancer(Globenewswire)
2023-12-27 19:55
BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients(Globenewswire)
2023-12-19 19:40
BriaCell Reports Unprecedented Preliminary Survival and Clinical Benefit in Antibody-Drug Conjugate (ADC) Refractory Patient Subset(Globenewswire)
2023-12-05 20:31
BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS(Globenewswire)
2023-12-05 20:00
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit(Globenewswire)
2023-11-29 18:00
BriaCell Records New Responder with Remarkable Improvement of Eye-Bulging Metastatic Tumor(Globenewswire)
2023-11-02 20:31
BriaCell Reports Unprecedented Anti-Tumor Activity of its Next Generation Personalized Breast and Prostate Cancer Immunotherapies in Tumor Models at the 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND(Globenewswire)
2023-10-31 22:49
BCTX: Year in Review(Yahoo Finance)
2023-10-24 21:15
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate(Globenewswire)
2023-10-19 21:15
October is Breast Cancer Awareness Month BriaCell is Leading the Fight with its Innovative Technology(Globenewswire)
2023-10-17 21:00
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences(Globenewswire)

Page 2 of 5

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.